Phase 3 N=47 Randomized Quadruple-blind Treatment

Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome

Ischemic Stroke · Excitotoxicity · Memantine

Bottom Line

View on ClinicalTrials.gov: NCT02535611 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2020

Primary outcome: Primary: Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS) — 4.52; 5.75 score on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: Placebo (Drug); Memantine (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Mazandaran University of Medical Sciences
Primary completion: Oct 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS)	3.42; 4.4	—
PRIMARY Investigation of Disability by Modified Rankin Scale (mRS)	2.3; 2.3	—
SECONDARY Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS)	3.42; 4.4	—
SECONDARY Investigation of Disability by Modified Rankin Scale (mRS)	2.3; 2.3	—

Summary

The researchers aim to investigate the effect of memantine on stroke outcome in a randomized double-blind placebo-controlled clinical trial.

Eligibility Criteria

Inclusion Criteria

Presentation at first 24hrs of disease onset
Confirmation of ischemic stroke in MCA territory by imaging.
Accepted consent form

Exclusion Criteria

Allergy history to memantine
Stage 4 -5 renal failure base on Acute Kidney Injury Network criteria
Moderate to severe hepatic failure (Child-Pugh criteria, grade B and C)
History of epilepsy
History of dementia
History of memantine use in recent 6 months
Pregnancy or breastfeeding
Severe drug adverse effects

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02535611). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.